StockTipsArenaBeta

BUY Cipla Ltd. — Vaishali Parekh, Prabhudas Lilladher

BUYCipla Ltd.
Cipla share price target & all analyst calls

byVaishali Parekh, Prabhudas LilladherHorizon: 1–3 months1 Jun 2026via Business Today

Entry₹1,350Stated
Target₹1,550
Total upside +14.81% (call closed)
Stop lossNot given
At expiry₹1,4231 Sept 2026, 3:30 pm
Expired+5.41%auction close
Follow Vaishali Parekh for new calls(32% target hit, 31 closed calls)Get alertsWatch CIPLA for new buy/sell callsGet alertsSee 45 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 1 Sept 2026
10 supporting18 neutral21 opposing
Supports the BUY call (10)

Cipla shares gain after it inks cancer treatment drug licensing deal with Sino Biopharma arm

NewsCnbc-Tv18·1 Sept · today

(opens in new tab)

Cipla licenses experimental HER2 cancer drug for India, South Africa and five other markets

NewsCnbc-Tv18·31 Aug · today

(opens in new tab)

Cipla Ltd has signed an exclusive licensing agreement with SBP Group for Rolditamig Deuderuxtecan (TQB2102), a potential best-in-class HER2 bispecific ADC.

BSE · Company Update·31 Aug · today

(opens in new tab)

8 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·31 Aug · yesterday

2 other SEBI-registered advisors have active short-term BUY calls on this stock

Advisor consensus · same horizon·7 Jul · 2mo ago

Neutral / worth noting (18)

US FDA classifies Cipla subsidiary’s New York facility inspection as ‘Voluntary Action Indicated’

NewsCnbc-Tv18·29 Aug · 3d ago

(opens in new tab)

Cipla Pharma License Cancellation: FDA Withdraws Order After HC Raps It For Going "Overboard"

NewsNdtv-Profit·29 Aug · 3d ago

(opens in new tab)

Cipla shares slip after USFDA observations; Citi says no earnings impact, target at ₹1,700

NewsCnbc-Tv18·26 Aug · 6d ago

(opens in new tab)

Nifty, Sensex open lower; TCS, Eternal gain, Cipla, Maruti slip

NewsHbl·25 Aug · 1w ago

(opens in new tab)

Nifty, Sensex open lower on Iran sanctions, tech selloff; TCS, Eternal gain while Cipla, Maruti slip

NewsHbl·25 Aug · 1w ago

(opens in new tab)
Weighs against the BUY call (21)

Cipla Pharma license cancellation: FDA withdraws order after Bombay HC raps it for going 'overboard'

NewsCnbc-Tv18·29 Aug · 2d ago

(opens in new tab)

FDA Crackdown: Cipla Arm Loses Pune Drug Sales Licence For Storage Deficiencies, Illegal Ads

NewsNdtv-Profit·28 Aug · 3d ago

(opens in new tab)

Cipla gets seven USFDA observations for Pithampur plant after follow-up inspection

NewsCnbc-Tv18·25 Aug · 6d ago

(opens in new tab)

3 advisors have active long-term SELL calls on this stock

Advisor consensus · adjacent horizon·24 Jul · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Cipla

All analyst calls on Cipla

More from Vaishali Parekh, Prabhudas Lilladher

Every call and its outcome